Putnam Investments’s RAPT Therapeutics RAPT Stock Holding History

Putnam Investments’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$672K	Buy	3,378 +866	+34%	+$107K	﹤0.01%	893
2023 Q3	$334K	Sell	2,512 -22	-0.9%	-$3.59K	﹤0.01%	1045
2023 Q2	$379K	Sell	2,534 -81	-3%	-$12.6K	﹤0.01%	1008
2023 Q1	$384K	Sell	2,615 -112	-4%	-$22.7K	﹤0.01%	998
2022 Q4	$432K	Sell	2,727 -1	-0%	-$160	﹤0.01%	964
2022 Q3	$525K	Buy	2,728 +237	+10%	+$44.8K	﹤0.01%	930
2022 Q2	$364K	Buy	2,491 +1,146	+85%	+$153K	﹤0.01%	1034
2022 Q1	$237K	Sell	1,345 -1,300	-49%	-$246K	﹤0.01%	1147
2021 Q4	$777K	Buy	+2,645	New	+$707K	﹤0.01%	893

Other funds holding RAPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Putnam Investments's RAPT Position: Q4 2023 in Review

Putnam Investments increased its RAPT Therapeutics (RAPT) stake by 34% in Q4 2023, buying an estimated $107K and bringing the position to 3,378 shares worth $672K. The position accounts for ﹤0.01% of the portfolio, ranked #893.

Putnam Investments first reported a position in RAPT in Q4 2021 and has held it in 9 quarters since. The position peaked at $777K in Q4 2021. 108 funds tracked by Wall St. Rank hold RAPT as of Q4 2023.

Putnam Investments held 3,378 shares of RAPT Therapeutics worth $672K as of Q4 2023.
Putnam Investments bought 866 RAPT Therapeutics shares in Q4 2023, an estimated $107K.
RAPT Therapeutics made up ﹤0.01% of Putnam Investments's portfolio in Q4 2023, its #893 holding.
Putnam Investments first reported a position in RAPT Therapeutics in Q4 2021 and has held it in 9 quarters since.
Putnam Investments's RAPT Therapeutics position peaked at $777K in Q4 2021.
108 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q4 2023.

Based on Putnam Investments's 13F filing for Q4 2023, filed 14 Feb 2024.